Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emergent Suspends COVID-19 Vaccine API Manufacturing As US FDA Inspects Bayview Plant

Executive Summary

After discovery of viral vector cross-contamination, AstraZeneca quit, J&J took control and the FDA launched inspection.

You may also be interested in...



Coronavirus Update: J&J Highlights Positive Booster Shot Data

Also, Moderna completed the submission of the BLA for mRNA-1273’s FDA approval, Pfizer starts a rolling submission for a booster shot and Brii Biosciences announced data for its two-antibody antiviral cocktail, and Japan withdraws selected lots of Moderna's vaccine over contamination worries.

Memo To File: How US FDA Decided Which Janssen Vaccine Drug Substance Batches Were OK To Use

Two batches were authorized because they were made before production waste jammed Emergent BioSolutions' Bayview plant.

What To Do When Last Pandemic’s Answer To The Next Pandemic Falters: Point Fingers

US congressional ‘coronavirus crisis’ panel explores Emergent BioSolutions COVID-19 vaccine launch failures while scoring points about private sector support.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144179

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel